Tenaya Therapeutics Stock Performance
| TNYA Stock | USD 3.29 0.33 11.15% |
On a scale of 0 to 100, Tenaya Therapeutics holds a performance score of 7. The entity has a beta of 0.44, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tenaya Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tenaya Therapeutics is expected to be smaller as well. Please check Tenaya Therapeutics' skewness, and the relationship between the value at risk and day median price , to make a quick decision on whether Tenaya Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Tenaya Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Tenaya Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 8.51 | Five Day Return 45.71 | Year To Date Return 10.87 | Ten Year Return (76.74) | All Time Return (76.74) |
1 | Acquisition by Column Group Iii Gp, Lp of 2222222 shares of Tenaya Therapeutics at 4.5 subject to Rule 16b-3 | 09/26/2024 |
2 | Tenaya Therapeutics, Inc. Given Consensus Rating of Buy by Analysts | 10/10/2024 |
3 | Acquisition by Burroughs Amy L. of 34000 shares of Tenaya Therapeutics at 2.04 subject to Rule 16b-3 | 10/18/2024 |
4 | Heres Why Were Watching Tenaya Therapeutics Cash Burn Situation | 11/01/2024 |
5 | Disposition of 2258 shares by Chihiro Saito of Tenaya Therapeutics at 2.12 subject to Rule 16b-3 | 11/18/2024 |
6 | Tenaya Therapeutics Buy Rating Reiterated at HC Wainwright | 11/25/2024 |
7 | Tenaya shares retain Buy rating, price target on trial update | 11/26/2024 |
| Begin Period Cash Flow | 95.7 M |
Tenaya |
Tenaya Therapeutics Relative Risk vs. Return Landscape
If you would invest 253.00 in Tenaya Therapeutics on September 1, 2024 and sell it today you would earn a total of 76.00 from holding Tenaya Therapeutics or generate 30.04% return on investment over 90 days. Tenaya Therapeutics is currently generating 0.6845% in daily expected returns and assumes 7.594% risk (volatility on return distribution) over the 90 days horizon. In different words, 67% of stocks are less volatile than Tenaya, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tenaya Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tenaya Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tenaya Therapeutics, and traders can use it to determine the average amount a Tenaya Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0901
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TNYA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.59 actual daily | 67 67% of assets are less volatile |
Expected Return
| 0.68 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Tenaya Therapeutics is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tenaya Therapeutics by adding it to a well-diversified portfolio.
Tenaya Therapeutics Fundamentals Growth
Tenaya Stock prices reflect investors' perceptions of the future prospects and financial health of Tenaya Therapeutics, and Tenaya Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tenaya Stock performance.
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 195.7 M | ||||
| Shares Outstanding | 79.22 M | ||||
| Price To Book | 2.31 X | ||||
| EBITDA | (122.51 M) | ||||
| Net Income | (124.08 M) | ||||
| Cash And Equivalents | 180.92 M | ||||
| Cash Per Share | 4.37 X | ||||
| Total Debt | 12.42 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 9.91 X | ||||
| Book Value Per Share | 1.42 X | ||||
| Cash Flow From Operations | (102.07 M) | ||||
| Earnings Per Share | (1.44) X | ||||
| Market Capitalization | 260.64 M | ||||
| Total Asset | 170.51 M | ||||
| Retained Earnings | (403.28 M) | ||||
| Working Capital | 88.85 M | ||||
About Tenaya Therapeutics Performance
By analyzing Tenaya Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Tenaya Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Tenaya Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Tenaya Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (752.09) | (789.69) | |
| Return On Tangible Assets | (0.73) | (0.76) | |
| Return On Capital Employed | (0.89) | (0.93) | |
| Return On Assets | (0.73) | (0.76) | |
| Return On Equity | (0.89) | (0.85) |
Things to note about Tenaya Therapeutics performance evaluation
Checking the ongoing alerts about Tenaya Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tenaya Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tenaya Therapeutics is way too risky over 90 days horizon | |
| Tenaya Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (124.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tenaya Therapeutics currently holds about 180.92 M in cash with (102.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tenaya Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Tenaya shares retain Buy rating, price target on trial update |
- Analyzing Tenaya Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tenaya Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Tenaya Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tenaya Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tenaya Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tenaya Therapeutics' stock. These opinions can provide insight into Tenaya Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Tenaya Stock analysis
When running Tenaya Therapeutics' price analysis, check to measure Tenaya Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenaya Therapeutics is operating at the current time. Most of Tenaya Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenaya Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenaya Therapeutics' price. Additionally, you may evaluate how the addition of Tenaya Therapeutics to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |